Cartesian reports Q2 2026 financials, funding to 2028

Cartesian Therapeutics reported Q2 2026 financials, noting a cash balance of roughly $149 million and a non-dilutive credit facility set to extend runway. The company updated on its Descartes-08 pipeline trials in myasthenia gravis, myositis, and juvenile dermatomyositis with several data readouts expected between late 2026 and early 2027.